Taysha Gene Therapies signs commercial supply deal with Catalent for TSHA-102 Rett syndrome therapy

Reuters2026/08/03 12:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Taysha Gene Therapies signed a commercial supply agreement naming Catalent as primary commercial manufacturer for TSHA-102, its Rett syndrome gene therapy.
Catalent will provide GMP manufacturing at its FDA-licensed gene therapy facility in Harmans, Maryland, contingent on FDA approval.
Deal expands a partnership in place since 2020, securing long-term manufacturing capacity ahead of a potential U.S. launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Taysha Gene Therapies signs commercial supply deal with Catalent for TSHA-102 Rett syndrome therapy

You may also like

Crypto prices